In Vivo Alzheimer Proteomics

NATerminatedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 8, 2013

Primary Completion Date

May 22, 2018

Study Completion Date

May 22, 2018

Conditions
Probable Alzheimer DiseaseParkinson DiseaseNeurological Disease Without Cognitive DegradationBrain TraumaAcute Hydrocephaly
Interventions
BIOLOGICAL

administration of stable isotope-labelled leucine-

\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours

OTHER

collection of CSF, blood, urine, saliva

\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours

Trial Locations (1)

34295

Laboratoire de Biochimie et Protéomique Clinique, CHU Montpellier, Montpellier

Sponsors
All Listed Sponsors
collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

collaborator

University Hospital, Clermont-Ferrand

OTHER

collaborator

International Atomic Energy Agency

OTHER_GOV

lead

University Hospital, Montpellier

OTHER

NCT02263235 - In Vivo Alzheimer Proteomics | Biotech Hunter | Biotech Hunter